Dive Brief:

概要：

After changing its name and focus, Cullinan Therapeutics is beefing up its autoimmune disease pipeline by

在更改名称和重点后，Cullinan Therapeutics 正在加强其自身免疫疾病管线

licensing an experimental drug from China

从中国获得一种试验性药物的许可

.

。

The company will pay Genrix Bio $20 million up front for the rights to a bispecific T cell engager called velinotamig. Genrix is then eligible to receive as much as $692 million in payments for reaching certain development, regulatory and sales goals, plus tiered royalties.

该公司将向 Genrix Bio 支付 2000 万美元的预付款，以获取一种名为 velinotamig 的双特异性 T 细胞接合器的权利。Genrix 还有资格获得高达 6.92 亿美元的付款，用于达成特定的开发、监管和销售目标，以及分级特许权使用费。

As part of the deal announced Wednesday, Cullinan will get the rights to the therapy in every country except China. The company plans to build on a Phase 1 study that Genrix will start this year in autoimmune disease in China, then take over development in that area.

根据周三宣布的协议，Cullinan将获得除中国以外所有国家的该疗法权利。该公司计划基于Genrix今年将在中国启动的自身免疫疾病一期研究，然后接手该领域的开发工作。

Dive Insight:

深入洞察：

Cullinan is one of many companies chasing the promise of a reset for the body’s immune system. Previously known as Cullinan Oncology, the

Cullinan 是众多追逐人体免疫系统重启希望的公司之一。该公司之前名为 Cullinan Oncology，

company changed its name

公司更改了名称

in April 2024 and undertook a “refinement” of its cancer therapy pipeline as it turned toward inflammatory conditions.

2024年4月，并对其癌症治疗管道进行“优化”，转向炎症性疾病。

Promising results from

结果有望

an academic study in Germany

德国的一项学术研究

showed that cell therapies might be able to drive hard-to-treat autoimmune diseases, like lupus, into remission. The findings sparked a

显示细胞疗法可能能够使难以治疗的自身免疫性疾病（如狼疮）得到缓解。这些发现引发了

wave of investment in cell therapies

细胞疗法的投资浪潮

for inflammatory disorders, with many companies

针对炎症性疾病，许多公司

once focused

一旦集中注意力

on cancer

关于癌症

joining the fray.

加入混战。

But

但是

early data have been mixed

早期数据参差不齐。

. And there’s a high bar for entry for CAR-T cell therapies, which are expensive to manufacture, may carry dangerous side effects and typically involve chemotherapy to prepare the body for treatment. Some companies in the field, including

. 而CAR-T细胞疗法的准入门槛很高，其制造成本昂贵，可能带来危险的副作用，并且通常需要通过化疗来为治疗做准备。该领域的一些公司，包括

Kyverna Therapeutics

基维纳治疗学公司

, have suffered

，已经遭受了苦难

share declines and reshuffled leadership

股票下跌和重组领导层

.

。

Dual-acting antibodies known as T-cell engagers may offer a more convenient alternative. Their promise has prompted a gold rush among

双效抗体，即T细胞结合剂，可能提供一种更便捷的替代方案。它们的潜力引发了一场淘金热。

venture investors

风险投资者

as well as pharmaceutical companies, including

以及制药公司，包括

GSK

葛兰素史克

and

和

Merck & Co.

默克公司

As with Cullinan, a number of the deals involved

与库利南一样，许多交易涉及其中。

assets originally from China

原产于中国的资产

.

。

Velinotamig is designed to target BCMA, a protein on the surface of the B cells that malfunctions in many autoimmune conditions. It’s shown promise in a Phase 2 study of patients with multiple myeloma, Cullinan said. And Cullinan plans to advance a form of the medicine under development by Genrix that can be injected rather than administered with an intravenous infusion, analysts with William Blair wrote in a research note..

Velinotamig旨在靶向BCMA，一种在B细胞表面存在的蛋白质，该蛋白质在许多自身免疫疾病中发生功能异常。Cullinan表示，它在多发性骨髓瘤患者的二期研究中显示出潜力。威廉布莱尔的分析师在一份研究报告中写道，Cullinan计划推进由Genrix开发的一种可注射形式的药物，而非通过静脉输注给药。

Cullinan said its latest acquisition will complement the development of another bispecific called CLN-978, which binds to a different B cell protein called CD19. Originally designed to treat B-cell non-Hodgkin lymphoma, Cullinan is now testing CLN-978 as a therapy for lupus.

库利南表示，其最新的收购将有助于另一种名为CLN-978的双特异性抗体的开发，该抗体结合到一种不同的B细胞蛋白CD19。最初设计用于治疗B细胞非霍奇金淋巴瘤的CLN-978，现在库利南正在测试将其作为狼疮的治疗方法。